塞德斯醫療 CLDX 深 滬
等待開盤 10-16 09:30:00 美东时间
27.34
+0.870
+3.29%
華盛通- 最 高27.73
- 今 開26.21
- 成交量 97.88万股
- 最 低 26.10
- 昨 收 26.47
- 總市值 18.16亿
- 52周最高 29.38
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 14.40
- 委 比 28.65%
- 總股本 6640.65万
- 歷史最高 582.60
- 量 比 0.95
- 振 幅 6.16%
- 歷史最低 1.50
- 每 手 1
- 風險率 3.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Analyst Expectations For Celldex Therapeutics's Future
Analysts' ratings for Celldex Therapeutics (NASDAQ:CLDX) over the last quarter ...
10-14 04:01
Barclays Initiates Coverage On Celldex Therapeutics with Underweight Rating, Announces Price Target of $25
Barclays analyst Etzer Darout initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Underweight rating and announces Price Target of $25.
10-13 20:17
Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study
Eupraxia's Cohort 9 RESOLVE trial data showed durable remission, improved tissue health, and strong safety, supporting Phase 2b expansion.
09-30 22:40
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Canaccord Genuity Maintains Buy on Celldex Therapeutics, Maintains $62 Price Target
Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $62 price target.
09-17 21:35
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
Celldex Therapeutics announced that its management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 3:20 pm ET. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event. Celldex is focused on developing antibody-based therapies for allergic, inflammatory, and autoimmune disorders. For more information, visit www.cellde...
09-09 13:01
Celldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria Treatment
Celldex Therapeutics (($CLDX)) announced an update on their ongoing clinical st...
08-28 00:44
美股大行评级 | 潜在涨幅166.67%！美银证券上调Rocket Pharmaceuticals目标价至10美元，评级升至"买入"
今日重点评级关注：美银证券：上调Rocket Pharmaceuticals评级至"买入"，目标价从4美元升至10美元；花旗：维持小鹏汽车"买入"评级，目标价从29美元升至29.4美元
08-21 19:00
Celldex药物二期试验结果公布后股价重挫
美股周三早盘，生物技术公司Celldex Therapeutics（CLDX）股价重挫9.5%，其Barzolvolimab药物二期试验虽达到主要终点但未能...
08-20 22:27
